Literature DB >> 18435917

C/EBP and C-Myb sites are important for the functional activity of the human myeloperoxidase upstream enhancer.

Congjun Yao1, Zhenyu Qin, Kimberly N Works, Garth E Austin, Andrew N Young.   

Abstract

Myeloperoxidase (MPO), an enzyme active against bacterial and fungal infections, is expressed specifically in myeloblasts and promyelocytes and minimal in other cell types. We recently identified and partially characterized an upstream enhancer located between -4100 and -3844 bp of the MPO gene. We showed that an AML1 site contributes to enhancer activity and specificity. We now demonstrate three additional footprints within the MPO enhancer and provide evidence that C/EBP and c-Myb sites contribute to its functional, tissue-specific activity. This distal enhancer appears to play an important role in the control of MPO transcription during differentiation of myeloid cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18435917     DOI: 10.1016/j.bbrc.2008.04.065

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

1.  Suppressor of cytokine signaling 3 inhibits LPS-induced IL-6 expression in osteoblasts by suppressing CCAAT/enhancer-binding protein {beta} activity.

Authors:  Chunguang Yan; Jay Cao; Min Wu; Wei Zhang; Tao Jiang; Aihiko Yoshimura; Hongwei Gao
Journal:  J Biol Chem       Date:  2010-09-28       Impact factor: 5.157

2.  Expression of myeloperoxidase in acute myeloid leukemia blasts mirrors the distinct DNA methylation pattern involving the downregulation of DNA methyltransferase DNMT3B.

Authors:  H Itonaga; D Imanishi; Y-F Wong; S Sato; K Ando; Y Sawayama; D Sasaki; K Tsuruda; H Hasegawa; Y Imaizumi; J Taguchi; H Tsushima; S Yoshida; T Fukushima; T Hata; Y Moriuchi; K Yanagihara; Y Miyazaki
Journal:  Leukemia       Date:  2014-01-10       Impact factor: 11.528

3.  Expression of myeloperoxidase and gene mutations in AML patients with normal karyotype: double CEBPA mutations are associated with high percentage of MPO positivity in leukemic blasts.

Authors:  Shinya Tominaga-Sato; Hideki Tsushima; Koji Ando; Hidehiro Itonaga; Yoshitaka Imaizumi; Daisuke Imanishi; Masako Iwanaga; Jun Taguchi; Takuya Fukushima; Shinichiro Yoshida; Tomoko Hata; Yukiyoshi Moriuchi; Kazutaka Kuriyama; Hiroyuki Mano; Masao Tomonaga; Yasushi Miyazaki
Journal:  Int J Hematol       Date:  2011-06-16       Impact factor: 2.490

4.  Overexpression of ZNF342 by juxtaposition with MPO promoter/enhancer in the novel translocation t(17;19)(q23;q13.32) in pediatric acute myeloid leukemia and analysis of ZNF342 expression in leukemia.

Authors:  Kathryn S Poland; Deborah L Shardy; Mohammed Azim; Rizwan Naeem; Robert A Krance; ZoAnne E Dreyer; E Shannon Neeley; Nianxiang Zhang; Yi Hua Qiu; Steven M Kornblau; Sharon E Plon
Journal:  Genes Chromosomes Cancer       Date:  2009-06       Impact factor: 5.006

5.  Regulation of the Flt3 Gene in Haematopoietic Stem and Early Progenitor Cells.

Authors:  Giacomo Volpe; Mary Clarke; Paloma Garcìa; David Scott Walton; Alexandros Vegiopoulos; Walter Del Pozzo; Laura Patricia O'Neill; Jonathan Frampton; Stéphanie Dumon
Journal:  PLoS One       Date:  2015-09-18       Impact factor: 3.240

6.  Impact of microRNA-130a on the neutrophil proteome.

Authors:  Corinna Cavan Pedersen; Jan Christian Refsgaard; Ole Østergaard; Lars Juhl Jensen; Niels Henrik Helweg Heegaard; Niels Borregaard; Jack Bernard Cowland
Journal:  BMC Immunol       Date:  2015-11-25       Impact factor: 3.615

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.